70% of patients had coamplifications of receptor tyrosine kinase or other cancer-promoting genes, including MET, KRAS, FGFR1, IGFR1, SRC and VEGFA18–20, potentially associated with resistance to EGFR-inhibitors (figure 3C). This evidence concerns the gene EGFR and cancer.